BOSTON, May 13, 2021 /PRNewswire/— Valo Health LLC (Valo), the technology company that is using human-centric data and artificial intelligence computation to transform and accelerate the drug discovery and development process, announced today that its CEO and founder, David Berry, will present at the UBS Global Healthcare Virtual Conference on May 25th at 4:00 pm Eastern Time.
The presentation will be webcast live and available for replay for 30 days on the investor relations page of the Valo website.
Valo Health, LLC (Valo) is a technology company that is using human-centric data and artificial intelligence computation to transform the drug discovery and development process. As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™, a fully integrated, computational, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com.
Investors: Graeme Bell, Chief Financial Officer
Media: Jennifer Hanley, VP Corporate Communications